GLP-1 Receptor Agonist Therapy

Medically prescribed GLP-1 receptor agonist injections (including semaglutide) as part of Phoenix Medical Group's supervised weight management and metabolic health programme.

Phoenix Medical Group prescribes GLP-1 receptor agonists as a pharmacological component of its weight management programme for patients who meet clinical criteria. GLP-1 (glucagon-like peptide-1) receptor agonists work through multiple complementary mechanisms: they act on the hypothalamus to reduce appetite and food cravings, stimulate glucose-dependent insulin release, suppress glucagon secretion, and slow gastric emptying to prolong post-meal satiety. These combined effects produce clinically significant weight reduction alongside improvements in glycaemic control, making GLP-1 medications particularly valuable for patients with overweight or obesity complicated by insulin resistance, pre-diabetes, or type 2 diabetes. At Phoenix Medical, GLP-1 therapy is initiated by a GP following a full health assessment and is embedded within a structured weight management programme rather than offered as a standalone prescription. The attending doctor monitors the patient's response, manages any side effects (nausea, gastrointestinal discomfort), and adjusts dosing progressively. Ongoing follow-up ensures the medication is working in concert with lifestyle modifications for sustained outcomes. The programme is available across the clinic network, allowing patients to access follow-up care at whichever location is most convenient.